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Abstract
Materials and methods This review focuses on the role of
antibody sialylation and methods for its quantitation. The
recent attribution of the anti-inflammatory activity of IgG to
thesialylationofitsglycansintheFcregionhasraisedinterest
in the fine structure and analysis of the glycans. The anti-
inflammatory fraction of intravenous IgG could be isolated
with the Sambucus nigra lectin. Experimental strategies for
the assessment of antibody sialylation are discussed.
Results Thorough analysis of the lectin-binding fraction
revealed that the antibody Fc region only binds to S. nigra
lectin when two sialic acids are present, whereas for other
glycoprotein ligands, one sialic acid appears sufficient.
Keywords Antibody glycosylation.sialic acid.IVIG.
anti-inflammatory
Introduction
Antibody glycosylation constitutes the molecular founda-
tion of a number of highly interesting features, including
increased cytotoxic toxicity of nonfucosylated IgG or
diminished efficacy conferred by sialylation, as has been
discussed in recent reviews [1, 2]. The groundbreaking
articles by Anthony et al. [3] and Kaneko et al. [4], on the
other hand, established Fc sialylation as a key feature for
the anti-inflammatory activity of intravenous IgG (IVIG).
Emphasizing the immunology, these articles, however, did
not adequately define the meaning of “sialylation”. The
same group also suggested that sialylation of antibodies
may be adapted to the needs of the immune system, as
sialylation of serum-derived IgG was greatly diminished
after active immunization of mice [4]. In a more recent
study, increased sialylation and galactosylation were found
on purified, antigen-specific IgG (alloantibodies) from
pregnant mothers [5]. Along with a concomitant decrease
of fucosylation, this also presents an adaptation of IgG
glycosylation to respective homeostatic requirements but in
the opposite direction. Obviously, such studies depend on
reliable quantitative analysis of neutral and sialylated
antibody N-glycans. In this review, we discuss promising
experimental approaches aimed at the unbiased analysis of
all IgG glycoforms and present recent results, where
quantitative data on antibody glycosylation have brought
unexpected insight into the structural basis of a biological
function of glycans. A more comprehensive discussion on
glycosylation analysis in general can be found in reviews
with a broader scope, such as that of Huhn et al. [6].
Strategies for IgG Glycosylation Analysis
The bewildering variety of approaches for glycosylation
analysis falls into two distinct categories. One strategy
works with released glycans. The second strategy analyzes
glycopeptides, where the Fc glycosylation can be analyzed
site specifically without interference by Fab glycans or
other contaminating glycoproteins [7, 8]. Glycopeptides
from the Fab region can, however, only be analyzed in the
case of monoclonal antibodies (mAbs). With polyclonal
IgG, the glycopeptide-based approaches inherently ignore
part of the whole picture.
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optionally, S-alkylated, digested with trypsin, and the
peptides are subjected to LC-ESI-MS [7–11]. Variations of
this approach analyze the glycopeptides by MALDI-TOF
MS following their isolation by either reversed-phase high-
performance liquid chromatography (HPLC) or some
means of glycan-specific capturing [6]. This step, however,
potentially deprives the analyst of information about the
extent of glycan truncation or incomplete site occupancy.
An extreme variety of the “glycopeptide” approach uses
ESI-MS of intact antibodies [9, 10, 12]. ESI-MS analysis of
individual heavy and light chains obtained by reduction is
less in danger of occluding subtle mass differences. This
may be less of a concern, however, given the enormous
resolution powers of the latest generation mass spectrom-
eters of the Q-TOF and orbitrap type (and certainly of the
ion-cylcotron type). Intact antibody analysis gives informa-
tion on the combination of glycoforms in the assembled
antibody. Information on glycan pairing has also been
obtained from papain-derived IgG-Fc preparations [13, 14].
In regard to the glycan strategy, it is noteworthy to point
out that all N-glycans of the sample, including those in the
Fc and the Fab fragments and those from impurities, are
released and analyzed together.
The methods dealing with free glycans again fall into
two categories: chromatographic and mass spectrometric
methods, which come together in their Hegelian synthesis,
LC-MS [6, 15]. HPLC is usually performed with fluores-
cently labeled glycans, with 2-aminobenzoic acid and its
amide being the most widely used reagents [16]. One
reason for this preference over the older 2-aminopyridine is
the milder reaction conditions. However, conditions for 2-
aminopyridine can be chosen that bring about a similarly
low degree of desialylation as 2-aminobenzamide (Table I).
In any case, α2,3-linkages are more prone to hydrolysis
than α2,6-linkages [16].
Concomitant Analysis of Neutral and Sialylated
N-Glycans
Underivatized glycans can be analyzed by mass spectrom-
etry, which, however, is inherently problematic when
analytes of different dissolved-state charge are compared.
In MALDI-MS, neutral and sialylated glycans can be
analyzed separately using different matrices and ion
polarity, or turned into neutral species by permethylation
[6]. In ESI-MS, all types of sugars can be observed in both
ion modes, however, with different detection sensitivity
(see next section).
A recent interlaboratory study insinuated that compara-
tive quantitation of neutral and sialylated N-glycans (from
antibodies) is a task that is still beyond current technical
abilities [17]. The study compared the ratios of neutral,
monosialylated, and disialylated glycans of IgG as obtained
from 10 laboratories using various methods. Values from
about 6% to 26% for monosialylated glycans and 1% to
13% for disialylated glycans in human IgG were reported
[17]. The study revealed a glaring difference between
chromatographic and mass spectrometric methods, a devi-
ation that was neither found by another large study [11], nor
by the authors of this review.
The fluorescence yield of glycans labeled (e.g., with 2-
aminobenzamide) can be assumed to be independent of
terminal oligosaccharide modifications. Thus, peak areas
are understood as faithfully reflecting the amount of a given
oligosaccharide, although the peak area may to some extent
be influenced by the solvent composition changing during
chromatography, e.g., by normal-phase HPLC on amide-
silica [18] and by insufficiently separated components.
More reliable results may be obtained with blends of pure
compounds than with natural glycan mixtures.
A comparison of the ratios obtained by normal-phase
HPLC and ESI-MS of glycopeptides revealed a good match
between the two methods [7]. This indicated that both
results essentially reflected the real composition. This was
not at all the case when free glycans were subjected to LC-
ESI-MS in negative mode, where disialylated sugars gave
disproportionately large peaks. In contrast, positive mode
detection yielded peak ratios similar to those obtained by
fluorescence HPLC [19].
Glycosylation of IgG-Update
N-glycans on IgG are variations on the theme of “dianten-
nary glycan with fucose, sialic acid, and bisecting
GlcNAc.” Chromatographic analyses by reversed- and
normal-phase HPLC gave a valuable synopsis including
resolution of isomers [18, 20, 21]. The data from this
pioneering period are still valid. Minor corrections were
Table I Sialic acid loss by reductive amination as determined by
normal-phase HPLC
α2,6 (%) α2,3 (%) Yield (%)
AB 1 1.7 4.9 90
AB 2 0.5 1.2 60
PA 1 13.6 81.9 95
PA 2 2 5.2 90





3–4) with 2-aminobenzamide was performed by the classical
method [16] for 2 hours at 70°C (AB 1) or overnight at 37°C (AB 2).
Derivatization with 2-aminopyridine was done by the original overnight
method (PA 1) or by the modified mild procedure (PA 2) [16].
Derivatization yield was determined by ESI-MS.
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abundance of disialylated structures in the Fc region [8, 22],
which tended to be overestimated in earlier studies. This
was probably due to contamination of Fc preparations with
Fab fragments. (A comprehensive table of the glycans that
occur on IgG and Fc and Fab fragments with a “Rosetta
stone” of the relevant structure names and schemes can be
found at http://www.proglycan.com.)
Monogalactosylated glycans from IgG show a preponder-
anceoftheisomerwithgalactoseonthe6-arm[18, 20], which
arises from the special steric situation of the Fc glycans in
IgG1. Remarkably, in IgG2, the AGnF and GnAF isomers
occur in even amounts as found on myeloma antibodies [18,
20] as well as on isolated IgG2 glycopeptides from
polyclonal IgG (data not shown). Enzyme specificity is the
reason for the strong-arm preference of IgG sialylation [18,
20], which was found to occur on both Fab and Fc glycans
[22]. This topology of monosialylated N-glycans was
recently corroborated by a nuclear magnetic resonance study
[23]. Bisected glycans are more prominent in the Fab region,
where even the platonic ideal of a disialylated bisected and
fucosylated structure can be found.
The amount of variable region glycosylation was
estimated at 20% from sequence database entries [24] and
r e p o r t e dt ob e1 5 %t o2 0 %[ 20]o r2 5 %[ 25], but
experimental evidence for these figures is not readily
accessible. We thus attempted a recalculation of the degree
of Fab glycosylation. Among Fab glycans, 46.2% are
sialylated [22]. This Fab fraction constitutes 12.3% of all
Fab fragments as revealed by chromatography on a sialic
acid–binding lectin. This translates into 26.7% of Fab
fragments being glycosylated with an error estimate of
±2.5%, which should also cover errors due to a possible
small amount of diglycosylated Fabs.
Lectin Fractionation of IVIG
Kaneko and colleagues [4] found that the Sambucus nigra
agglutinin (SNA)-binding fraction of IVIG had a roughly
10-fold higher anti-inflammatory potency compared with
total IVIG. The relative potency of the nonbinding fraction
has not been reported. However, as 12% of IVIG bind to
SNA [22], one might speculate that this lectin-affinity
fraction holds the entire anti-inflammatory activity, with the
nonbinding fraction being essentially ineffective. At first
glance, these results appear to match nicely with the 11% of
sialylated N-glycans found in the Fc region [8, 22]. The
situation, however, is more complex.
Site-specific analysis of the SNA binding and nonbinding
fractions of IVIG revealed no significant difference in Fc
sialylation [22]. The obvious conclusion was that the
fractionation of IgG on SNA was solely based on the N-
glycans in the variable domains, whereas the sialoglycans in
the CH2 domain were inaccessible to the lectin. This view
was seemingly supported by SNA fractionation of isolated
Fab fragments [22]. However, it harshly contradicts the
earlier conclusion that the anti-inflammatory activity
depended on sialylation of the Fc region N-glycans [3, 4].
Stadlmann and coworkers might have put that contradiction
on their banner, were it not for the mere coincidence that
they came to analyze the mAb 4E10, produced in Nawalma
cells, which had an unusually high degree of monosialylated
N-glycans. These glycans are α2,6-sialylated and confined to
the Fc region. If only Fab sialylation would confer SNA
binding, the 4E10-hum should not bind to this lectin.
Unexpectedly, a large fraction of the mAb did bind and
large amounts of monosialylated N-glycans were found in
both the binding and nonbinding fraction. This phenomenon
could be explained by looking at the whole antibody with its
2 Fc glycans. The stochastic prediction of the percentage of
mAbs with 0, 1, and 2 sialic acids matched the experimen-
tally determined value of SNA binding of 43% only under
the premise that two sialic acids were required for SNA
binding. Such glycoforms could either contain disialylated
and nonsialylated glycans (S2-S0 glycoform) or two mono-
sialylated N-glycans (S1-S1 glycoform) (Fig. 1). These
considerations assume that all combinations of glycans occur
with equal probability. At least up to the S1–S0 combination,
this assumption is substantiated by ESI-MS analysis of Fc
fragments or whole antibody [13].
Addressing IVIG with this finding in mind, we realized
that 11% of S1 glycans could result in about 1% of the S1–
S1 glycoform (Table II). Indeed, this correlates with the
result of fractionation of Fc on SNA [22]. Notably, this
requirement for two sialic acids for SNA binding does not
extend to other glycoproteins, as Fab fragments with one
sialic acid did bind (data not shown). We assume that the
polypeptide strands of the CH2 domain shield one sialic
acid residue. Denaturation should obstruct this shielding,
and indeed, heat treatment of the SNA-nonbinding IVIG
fraction led to strong SNA binding (Alfred Weber, personal
communication, 2009).
Kaneko and colleagues [4] found a significant increase
in anti-inflammatory efficacy for the SNA-retained fraction
of IVIG. As we have shown that the percentage of total
sialylated glycans in the Fc region is hardly altered by SNA
fractionation, this means that glycoforms with just one
sialic acid occur in both pools and must therefore be
regarded as more or less ineffective. From that, it was
argued that the double sialylation of IgG constitutes the
minimal requirement for both the binding to SNA and its
anti-inflammatory effect [22]. Hypothetically, the anti-
inflammatory power could also reside in glycoforms with
three or four sialic acids, for whose actual existence there is
currently no experimental evidence and would in theory
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(Table II). As it is very difficult to add sialic acid to IgG
beyond the S1–S1 glycoform [23], it appears important to
clarify whether such hypersialylation would increase the
anti-inflammatory potency. Such experiments could be
done with mAbs, where a separation according to the
number of sialic acids is possible. Considering the spatial
constraints in the Fc glycosylation pocket [2], a most
Fig. 1 Sialylation of the Fc
fragment. The Fc fragment of
an antibody (taken with Pymol
from 1HZH.PDB; top picture).
The CH2 domain in all conceiv-
able glycoforms in frontal view
and—except for the hypersialy-
lated glycoforms—in side view
(bottom picture). In the last row,
only a second sialic acid (purple
diamond) is exposed and acces-
sible to a lectin
Table II Calculated abundance of sialylated glycoforms of IgG. The
table on the left shows the combinations of glycans in the anti-HIV
mAb 4E10-hum [7]; the table on the right shows combinations of
glycans for human polyclonal IgG. p is the probability factor derived
from the percentage of glycans with 0, 1, or 2 sialic acids irrespective
of other structural features
mAb 4E10-hum IVIG
Sia # S0 S1 S2 Sia # S0 S1 S2
p 0.398 0.541 0.061 p 0.896 0.104 0.0005
S0 0.398 0.158 0.215 0.024 S0 0.896 0.8028 0.0932 0.0004
S1 0.541 0.215 0.293 0.033 S1 0.104 0.0932 0.0108 0.0001
S2 0.061 0.024 0.033 0.004 S2 0.0005 0.0004 0.0001 0.0000
SNA nonbinding (%) SNA binding (%) SNA nonbinding (%) SNA binding (%)
S1-S1 29.3 S1-S1 1.08
S0-S0 15.8 S2-S0 4.9 S0-S0 80.3 S2-S0 0.09
S1-S0 43.1 S2-S1 6.6 S1-S0 18.6 S2-S1 0.01
S2-S2 3.3 S2-S2 0.01
Sum 58.9 Sum 44.0 Sum 98.9 Sum 1.2
mAb indicates monoclonal antibody; IVIG, intravenous IgG; SIA, sialic acids; SNA, S. nigra agglutinin.
S18 J Clin Immunol (2010) 30 (Suppl 1):S15–S19interesting question to raise is “what is the impact of a high
degree of sialylation of Fc glycans on protein structure?”
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